» Articles » PMID: 31766246

Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements

Overview
Journal Biomolecules
Publisher MDPI
Date 2019 Nov 27
PMID 31766246
Citations 413
Authors
Affiliations
Soon will be listed here.
Abstract

Reactive oxygen species (ROS) play a pivotal role in biological processes and continuous ROS production in normal cells is controlled by the appropriate regulation between the silver lining of low and high ROS concentration mediated effects. Interestingly, ROS also dynamically influences the tumor microenvironment and is known to initiate cancer angiogenesis, metastasis, and survival at different concentrations. At moderate concentration, ROS activates the cancer cell survival signaling cascade involving mitogen-activated protein kinase/extracellular signal-regulated protein kinases 1/2 (MAPK/ERK1/2), p38, c-Jun N-terminal kinase (JNK), and phosphoinositide-3-kinase/ protein kinase B (PI3K/Akt), which in turn activate the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), matrix metalloproteinases (MMPs), and vascular endothelial growth factor (VEGF). At high concentrations, ROS can cause cancer cell apoptosis. Hence, it critically depends upon the ROS levels, to either augment tumorigenesis or lead to apoptosis. The major issue is targeting the dual actions of ROS effectively with respect to the concentration bias, which needs to be monitored carefully to impede tumor angiogenesis and metastasis for ROS to serve as potential therapeutic targets exogenously/endogenously. Overall, additional research is required to comprehend the potential of ROS as an effective anti-tumor modality and therapeutic target for treating malignancies.

Citing Articles

The Role of Reactive Oxygen Species in Colorectal Cancer Initiation and Progression: Perspectives on Theranostic Approaches.

Catalano T, Selvaggi F, Cotellese R, Aceto G Cancers (Basel). 2025; 17(5).

PMID: 40075600 PMC: 11899472. DOI: 10.3390/cancers17050752.


Irradiation-responsive PRDM10-DT modulates the angiogenic response in human NSCLC cells in an SP1-dependent manner via the miR-663a/TGF-β1 axis.

Huang H, Xu Y, Guo Z, Zhang M, Li W, Song Y J Transl Med. 2025; 23(1):235.

PMID: 40016776 PMC: 11866594. DOI: 10.1186/s12967-025-06273-0.


Innovations in Cancer Therapy: Endogenous Stimuli-Responsive Liposomes as Advanced Nanocarriers.

Torres J, Valenzuela Oses J, Rabasco-Alvarez A, Gonzalez-Rodriguez M, Garcia M Pharmaceutics. 2025; 17(2).

PMID: 40006612 PMC: 11858840. DOI: 10.3390/pharmaceutics17020245.


Emerging Approaches in Glioblastoma Treatment: Modulating the Extracellular Matrix Through Nanotechnology.

Horta M, Soares P, Leite Pereira C, Lima R Pharmaceutics. 2025; 17(2).

PMID: 40006509 PMC: 11859630. DOI: 10.3390/pharmaceutics17020142.


Activating transcription factor 3 induces oxidative stress and genotoxicity, transcriptionally modulating metastasis-related gene expression in human papillomavirus-infected cervical cancer.

Naderzadeh E, Kargar M, Mokhtari M, Farhadi A Virol J. 2025; 22(1):46.

PMID: 39994644 PMC: 11849226. DOI: 10.1186/s12985-025-02675-0.


References
1.
Donovan L, Lassman A . Chemotherapy Treatment and Trials in Low-Grade Gliomas. Neurosurg Clin N Am. 2018; 30(1):103-109. DOI: 10.1016/j.nec.2018.08.007. View

2.
Brewer T, Garcia F, Onak C, Carroll K, Chang C . Chemical approaches to discovery and study of sources and targets of hydrogen peroxide redox signaling through NADPH oxidase proteins. Annu Rev Biochem. 2015; 84:765-90. PMC: 6063359. DOI: 10.1146/annurev-biochem-060614-034018. View

3.
Megias-Vericat J, Montesinos P, Herrero M, Moscardo F, Boso V, Rojas L . Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy. Pharmacogenomics J. 2017; 18(2):301-307. DOI: 10.1038/tpj.2017.19. View

4.
Yang H, Villani R, Wang H, Simpson M, Roberts M, Tang M . The role of cellular reactive oxygen species in cancer chemotherapy. J Exp Clin Cancer Res. 2018; 37(1):266. PMC: 6211502. DOI: 10.1186/s13046-018-0909-x. View

5.
Han X, Sun S, Zhao M, Cheng X, Chen G, Lin S . Celastrol stimulates hypoxia-inducible factor-1 activity in tumor cells by initiating the ROS/Akt/p70S6K signaling pathway and enhancing hypoxia-inducible factor-1α protein synthesis. PLoS One. 2014; 9(11):e112470. PMC: 4226555. DOI: 10.1371/journal.pone.0112470. View